my country's special drugs for the treatment of COVID-19 are expected to be on the market soon

China's COVID-19 specific drugs have finally updated the "timetable", and one of the antibody combination drugs is expected to be approved for conditional listing as early as the end of the year

According to statistics, there are currently 6 kinds of drugs specifically developed for new coronary pneumonia in China

The R&D team has submitted conditional marketing application materials to the State Food and Drug Administration on October 9, and is expected to obtain conditional marketing approval before the end of December

Professor Zhang Linqi of Tsinghua University said: “Hundreds of antibodies have been isolated from the blood of patients recovering from new coronary pneumonia, and the two antibodies with the highest activity and strong complementarity have been screened

At the same time, the neutralizing antibody DXP604, jointly developed by Peking University's Xie Xiaoliang team and Danxu Biotechnology, was used as a "sympathetic drug" by Beijing Ditan Hospital when no other drugs were available

In addition, a new generation of androgen receptor antagonist "Prokalutamide" being developed by the pioneering pharmaceutical industry has been approved for emergency use in Paraguay

According to the relevant person in charge, the current research and development of effective drugs for the new coronavirus is mainly focused on the three major technical routes of blocking the virus from entering cells, inhibiting virus replication, and regulating the human immune system

 (Source: Internet, reference only)